|Bid||71.91 x 100|
|Ask||73.75 x 200|
|Day's Range||71.95 - 72.69|
|52 Week Range||55.06 - 75.04|
|PE Ratio (TTM)||18.82|
|Earnings Date||Jul 28, 2017|
|Dividend & Yield||2.56 (3.53%)|
|1y Target Est||75.41|
Gilead should cut itself in two. Here's why.
Gilead Sciences Inc on Wednesday reported lower second-quarter profits as use of its flagship hepatitis C drugs continued to decline, but the results still beat Wall Street estimates and the company raised its full-year sales outlook. After one-time items, Gilead earned $2.56 a share. Wall Street analysts, on average, had forecast adjusted earnings of $2.15 a share, according to Thomson Reuters I/B/E/S.
NEW YORK, NY / ACCESSWIRE / July 25th, 2017 / Traders News Source, a leading independent equity research and corporate access firm focused on small and mid-cap public companies is issuing a comprehensive ...